Chronic treatment with phentermine combined with fenfluramine lowers plasma serotonin

As expected on the basis of published research in both humans and animals, treatment with phentermine/fenfluramine lowers plasma 5-hydroxytryptamine [corrected], whereas treatment with phentermine had no significant effect. In light of these findings, future research should focus on mechanisms other...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of cardiology 2000-04, Vol.85 (7), p.913-915
Main Authors: Rothman, Richard B., Redmon, J.Bruce, Raatz, Susan K., Kwong, Christine A., Swanson, Joyce E., Bantle, John P.
Format: Article
Language:English
Subjects:
Administration, Oral
Biological and medical sciences
Cardiology
Cardiovascular disease
Diabetes Mellitus, Type 2 - blood
Diabetes Mellitus, Type 2 - complications
Diabetes Mellitus, Type 2 - drug therapy
Double-Blind Method
Drug therapy
Drug Therapy, Combination
Drug toxicity and drugs side effects treatment
Female
Fenfluramine - administration & dosage
Fenfluramine - pharmacokinetics
Fenfluramine - therapeutic use
Heart Valve Diseases - blood
Heart Valve Diseases - etiology
Heart Valve Diseases - prevention & control
Humans
Hypertension, Pulmonary - blood
Hypertension, Pulmonary - etiology
Hypertension, Pulmonary - prevention & control
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Phentermine - administration & dosage
Phentermine - pharmacokinetics
Phentermine - therapeutic use
Risk Factors
Serotonin - blood
Serotonin Uptake Inhibitors - administration & dosage
Serotonin Uptake Inhibitors - pharmacokinetics
Serotonin Uptake Inhibitors - therapeutic use
Sympathomimetics - administration & dosage
Sympathomimetics - pharmacokinetics
Sympathomimetics - therapeutic use
Toxicity: cardiovascular system
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:As expected on the basis of published research in both humans and animals, treatment with phentermine/fenfluramine lowers plasma 5-hydroxytryptamine [corrected], whereas treatment with phentermine had no significant effect. In light of these findings, future research should focus on mechanisms other than increased plasma 5-hydroxytryptamine [corrected] to explain how fenfluramine increases the risk of primary pulmonary hypertension and valvular heart disease.
ISSN:0002-9149
1879-1913
DOI:10.1016/S0002-9149(99)00896-6